New Drug Treats Cervical Cancer

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1097/01.NAJ.0000815420.91630.18

New Drug Treats Cervical Cancer

Diane S. Aschenbrenner

Tisotumab vedotin-tftv (Tivdak) has received accelerated approval to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Ocular adverse effects occurred in 60% of patients in clinical trials. To minimize this risk, nurses should follow the guidelines for premedication and required eye care.

Links

DOI PubMed

Journal

AJN, American Journal of Nursing

Authors

Diane S. Aschenbrenner